Dhuwit awis perusahaan: beigene.com (ONC)

Lambang korporat lan logo BeiGene Ltd. (ONC)

BeiGene Ltd efficiency is based on the expansion of Brukinsa and the optimization of R&D costs. The cash balance visualizes the dynamics of liquid reserves, where the indicator value is 5.83. This ensures access to the global healthcare markets of the US and China, while stable demand for targeted therapy guarantees an inflow of high-margin cash and operational business resilience.

Dana dhuwit perusahaan: BeiGene Oncology (ONC) kanggo 04.07.2022 - 21.11.2026

BeiGene Ltd. (ONC) - rincian metrik lan laporan keuangan

- indikator kapitalisasi bursa perusahaan:
Analisis kabeh metrik perusahaan:ONC BeiGene
Produk merek BeiGene

For the long-term investor, the financial stability of BeiGene Ltd (ONC) is determined by its ability to fund R&D without emergency borrowing. This metric tracks the daily balance of liquid assets, reflecting the rate of capital burn. By analyzing the company's cash position, one can assess the risk of a liquidity gap prior to drug commercialization. A sufficient reserve guarantees the completion of costly clinical trials, ensuring future business scalability through global sales.

Karo sapa BeiGene Ltd saingan

Dhuwit awis perusahaan HALO (Halozyme Therapeutics, Inc.)|Volume dana dhuwit perusahaan Revolution Medicines, Inc. (RVMD)|Volume dana dhuwit perusahaan AAPG (ascentage.com)|CG Oncology Inc (CGON) - Cadangan dhuwit perusahaan|URGN - Dana dhuwit perusahaan|Bicara Bio - Gunggung dana dhuwit perusahaan|PSNL: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan ERAS|Dhuwit awis perusahaan DCTH|Cadangan dhuwit perusahaan Y-mAbs Therapeutics Inc YMAB|Volume dana dhuwit perusahaan AURA|CADL (Candel Therapeutics, Inc.) - Sisa dhuwit perusahaan|Dana dhuwit perusahaan Accuray Inc ARAY|Aset likuid perusahaan SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Citius Oncology|HURA: Volume dana dhuwit perusahaan|Total volume dana dhuwit perusahaan TARA (Protara)|FATE (fatetherapeutics.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Aadi Bioscience WHWK|Volume dana dhuwit perusahaan TCRX|CSBR - Cadangan dhuwit perusahaan|XBiotech - Dhuwit awis perusahaan|CEL-SCI Corporation (CVM) - Cadangan dhuwit perusahaan|OSTX - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Dhuwit awis perusahaan|ANL (Adlai Nortye Ltd) - Dana dhuwit perusahaan|Dhuwit awis perusahaan VERU|Tempest Therapeutics (TPST) - Aset likuid perusahaan|Volume dana dhuwit perusahaan XLO|Dhuwit awis perusahaan Renovaro RENB|Volume dana dhuwit perusahaan MURA (Mural Oncology PLC)|KAPA - Dhuwit awis perusahaan|OnKure Therapeutics - Volume dana dhuwit perusahaan|w2.cytomed.sg - Gunggung dana dhuwit perusahaan|Curis Corp (CRIS) - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Apollomics Corp (APLM)|Dana dhuwit perusahaan Tharimmune|Volume dana dhuwit perusahaan advanbiomed.com|Dana dhuwit perusahaan Genprex, Inc (GNPX)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan